The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail

Wed, 20th Mar 2024 18:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Transense Technologies PLC - Bicester, Oxfordshire-based developer of specialist sensor systems for vehicles - Appoints Ryan Maughan as managing director with immediate effect. Maughan joined Transense on a part-time basis as business development director of SAWsense on December 1 2021.

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Appoints Cork Gully LLP as administrators. Says talks with creditors to establish the solvency of the business, have taken place, with a particular focus on finding solutions that would allow the group to continue trading on a lower cost model. However, to date, these discussions have not progressed sufficiently to establish the precise solvency status of the business. Therefore, due to this increased financial uncertainty the decision has been taken to appoint administrators. Stresses discussions with potential investors, partners and creditors will remain open throughout the administration process.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - Updates on return of capital to shareholders. Says that the level of cash within the company's portfolio against the net asset value as at March 6 has increased to over 40%. Therefore, anticipates that it will be able to undertake an issue and redemption of B shares on or around April 4. This will enable a return capital of around 26.0 pence per share to shareholders. Says this is significantly improved on the previous anticipated return of around GBP10 million, or 21.5p per share.

----------

BAE Systems PLC - London-based defence, aerospace and security company - Announces private placement of notes to institutional buyers. Notes to be issued consist of USD800 million in aggregate principal amount of 5.000% notes due 2027, USD1.25 billion in aggregate principal amount of 5.125% notes due 2029, USD500 million in aggregate principal amount of 5.250% notes due 2031, USD1.50 billion in aggregate principal amount of 5.300% notes due 2034 and USD750 million in aggregate principal amount of 5.500% notes due 2054. Net proceeds will be used to refinance USD4.0 billion in aggregate principal amount outstanding under the bridge loan facility agreement incurred to fund part of the acquisition price of Ball Aerospace, and for general corporate purposes. Notes the offering is expected to close on or about March 26.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Says Andrew Male and Paul Gurney have joined the Board of G2 Energy Ltd. Male is interim chief executive of Cloudbreak. Gurney is a non-executive director. Male states: "Paul and I look forward to working with G2 and their team in order to develop and enhance the production assets that G2 hold. Our primary focus will be to assist G2 in generating more revenue and looking at additional acquisitions that are accretive to the Cloudbreak investment and G2's underlying business operations."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.